Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Second Sight Medical Products's Return-on-Tangible-Asset or its related term are showing as below:
EYESW'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -278.76 Med: -164.73 Max: -12.79
Current: -12.79
During the past 10 years, Second Sight Medical Products's highest Return-on-Tangible-Asset was -12.79%. The lowest was -278.76%. And the median was -164.73%.
EYESW's Return-on-Tangible-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.595
vs EYESW: -12.79
Second Sight Medical Products (NAS:EYESW) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Second Sight Medical Products Return-on-Tangible-Asset Related Terms
Second Sight Medical Products Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products Return-on-Tangible-Asset Chart
EYESW vs SONX, LUCD, LHDX: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Second Sight Medical Products's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Second Sight Medical Products Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Second Sight Medical Products's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2022) net income data.
What does a Return-on-Tangible-Asset of -18.34% mean?
Second Sight Medical Products (EYESW) has a Return-on-Tangible-Asset of -18.34% as of Jun. 2022. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Second Sight Medical Products and its competitors.
Is Second Sight Medical Products' Return-on-Tangible-Asset too high?
Second Sight Medical Products' current Return-on-Tangible-Asset is -18.34%.
How does Second Sight Medical Products' Return-on-Tangible-Asset compare to SONX and LUCD?
Second Sight Medical Products' Return-on-Tangible-Asset of -18.34% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Second Sight Medical Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Second Sight Medical Products's current Return-on-Tangible-Asset is -18.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current Return-on-Tangible-Asset of -18.34%. The current Return-on-Tangible-Asset is -18.34%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current Return-on-Tangible-Asset is -18.34% as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Second Sight Medical Products Business Description
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYESW has been successfully added to your 
